446P - Impact of previous immunotherapy on chemotherapy efficacy in metastatic melanoma

Background

Chemotherapy alone is no longer adequate for the treatment of metastatic melanoma (MM). We sought to explore whether immunotherapy administered prior to chemotherapy affects the outcome of subsequent chemotherapy in Chinese melanoma patients.

Methods

From January 1, 2016 to December 31, 2021, 68 Chinese MM patients receiving chemotherapy at Zhejiang Cancer Hospital were divided into a non-immunotherapy group (non-IMT) and an immunotherapy group (IMT) based on whether they received immunotherapy prior to chemotherapy, and further divided into an IMT <180 group and an IMT >180 group based on whether the duration of immunotherapy exceeded 180 days group. Progression-free survival (PFS), and overall survival (OS) were assessed.

Results

Chinese patients had a higher mortality rate for acral melanoma (ALM) than for mucosal melanoma (MCM). Patients in the IMT group tended to have a better median PFS (210 days versus 218 days, p = 0.374) and median OS (236 days versus 293 days, p = 0.449) compared to patients in the non-IMT group. Patients in the IMT < 180 group also had better median PFS (234 days versus 518 days, p = 0.163) and median OS (284 days versus 191 days, p = 0.0494) compared to patients in the IMT > 180 group.

Conclusions

The effectiveness of chemotherapy may be related to the availability of immunotherapy prior to chemotherapy, and chemotherapy is more effective when the duration of immunotherapy is less than 180 days.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.